Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 99 results.
LastUpdate Updated on 22/11/2026 [07:35:00]
pdfxls
Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days
Results 1 to 25 of 99 nextPage  

CARTRIDGE AND METHOD FOR DILUTION OF TARGET ANALYTE

Publication No.:  EP4841260A1 18/11/2026
Applicant: 
SIEMENS HEALTHINEERS NEDERLAND B V [NL]
Siemens Healthineers Nederland B.V.
EP_4841260_PA

Absstract of: EP4841260A1

The present invention relates to a cartridge for the uptake and analysis of a fluid sample with respect to the presence and/or quantity of a target, comprising one or more reaction zones and one or more transport zones, which zones are designed for contacting of reagents with a sample, wherein said one or more zones comprise as reagent one or more free first interactor(s) of said target. Further envisaged is a system comprising the cartridge and a handheld device. Moreover, the present invention is directed to a method of reducing the active concentration of a target in a fluid sample as well as a use of the cartridge or system for immunological assays.

PROTEIN ANTIGEN COMBINATION FOR ALZHEIMER'S DISEASE DETECTION AND USE

Publication No.:  EP4841262A1 18/11/2026
Applicant: 
SHANGHAI ZHONGQI BIOTECHNOLOGY CO LTD [CN]
SHANGHAI ZHONGQI BIOTECHNOLOGY CO., LTD
EP_4841262_A1

Absstract of: EP4841262A1

The present disclosure belongs to the field of biological detection, and particularly relates to a protein antigen combination for detection of Alzheimer's disease (AD) and use thereof. The specific technical solution is as follows: An antigen combination is provided, wherein the antigen combination at least simultaneously includes any two of the following proteins: DOC2A, LGALS1, KDM4D, and ADARB1. The present disclosure provides several new protein antigens and the combination thereof, which can be used for early-screening detection or diagnosis of AD, and are particularly suitable for risk assessment and prediction prior to the onset of AD. Meanwhile, the protein antigens and the combination thereof can distinguish AD from other types of dementia, and can be further prepared into related reagents or kits according to needs.

COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATMENT OF NEURODEGENERATIVE AND MITOCHONDRIAL DISEASE

Publication No.:  US20260356842A1 12/11/2026
Applicant: 
MITOKININ INC [US]
MITOKININ, INC.
US_20260356842_A1

Absstract of: US20260356842A1

The present disclosure is directed to adenine analogs, methods of making adenine analogs, and methods of treating disorders associated with PINK1 kinase activity including, but not limited to, neurodegenerative diseases, mitochondrial diseases, fibrosis, and/or cardiomyopathy using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

ANTI-INTERLEUKIN-6 SINGLE-DOMAIN ANTIBODIES

Publication No.:  US20260356933A1 12/11/2026
Applicant: 
REES CHRISTOPHER [GB]
SEERAVE VENTURES LTD [GB]
REES Christopher
SEERAVE VENTURES LIMITED
US_20260356933_A1

Absstract of: US20260356933A1

0000 The present invention relates to single-domain antibodies (sdAbs) binding interleukin 6 (IL6). In particular, the invention relates to sdAbs that bind IL6 within a specific range of an on-rate constant and off-rate constant. The sdAbs of the present invention can associate and dissociate with IL6 in a continuous manner. The invention further relates to nucleic acids encoding anti-IL6 sdAbs, methods for detecting IL6, methods of treatment and diagnosis making use of the anti-IL6 sdAbs, methods for monitoring IL6 levels and apparatuses comprising the anti-IL6 sdAbs.

REMOVAL OF CD41+ AND/OR CD61+ PLATELET DERIVED EXTRACELLULAR VESICLES (PEVS)

Publication No.:  WO2026236212A1 12/11/2026
Applicant: 
AETHLON MEDICAL INC [US]
AETHLON MEDICAL, INC.
WO_2026236212_A1

Absstract of: WO2026236212A1

Described herein are methods and devices that deplete or reduce CD41+ and/or CD61+ Platelet Derived Extracellular Vesicles (PEVs), or fragments thereof, which improve the efficacy of therapies used for the treatment of various diseases, such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), vasculitis, Systemic Sclerosis (SS), cardiovascular disease, atherosclerosis, stroke, cancer, sepsis, Alzheimer's disease, a hemorrhagic disorder such as disseminated intravascular coagulation (DIC), thrombosis, a blood cell disorder, or any combination thereof. In particular, methods and devices employing extracorporeal devices that deplete CD41+ and/or CD61+ PEVs, or fragments thereof, present in a subject, are provided.

SYSTEMS, METHODS, AND KITS FOR DIAGNOSIS OR TREATMENT PLANNING USING EXTRACELLULAR VESICLES

Publication No.:  WO2026236730A1 12/11/2026
Applicant: 
UNIV WAKE FOREST HEALTH SCIENCES [US]
WAKE FOREST UNIVERSITY HEALTH SCIENCES
WO_2026236730_A1

Absstract of: WO2026236730A1

The inventors discovered methods to enrich small extracellular vesicles (sEVs) for neuron-derived sEVs (NDEs). Methods, systems, and kits for enriching sEVs from NDEs are disclosed herein. The methods comprise contacting a plurality of small extracellular vesicles (sEVs) with a binding reagent specific for a neuron-derived sEV (NDE)-specific marker to generate a binding reagent-NDE complex. The NDE-specific marker may be selected from synaptosome associated protein 25 (SNAP-25), glycoprotein M6A (GPM6A), BTB domain containing 17 protein (BTBD17), gamma-aminobutyric acid type A receptor subunit alpha1 (GABRA1), or a combination thereof.

IN VITRO METHOD FOR ASSESSING AND/OR MONITORING THE DEGREE OF INTESTINAL BARRIER INTEGRITY AND/OR PERMEABILITY IN A SUBJECT

Publication No.:  WO2026234294A1 12/11/2026
Applicant: 
VENTER PHARMA S L [ES]
VENTER PHARMA S.L.
WO_2026234294_A1

Absstract of: WO2026234294A1

The present invention refers to an in vitro method for assessing and/or monitoring the degree of intestinal barrier integrity and/or permeability in a subject.

MARKER FOR USE IN IDENTIFYING OR PREDICTING DISEASES OF THE MACULA

Publication No.:  WO2026234039A1 12/11/2026
Applicant: 
NOVAI LTD [GB]
NOVAI LTD
WO_2026234039_A1

Absstract of: WO2026234039A1

Methods of identifying, predicting, staging or prognosticating a disease of the macula in a subject, comprising identifying stressed cells in an image of the retina of a subject and assessing the arrangement of the one or more labelled cell stress marker positive cells using angular plot analysis.

METHODS AND SYSTEMS FOR TRANSPORTATION AND CULTURE OF BUOYANT TISSUE

Publication No.:  US20260357219A1 12/11/2026
Applicant: 
KELIOMICS INC [US]
Keliomics, Inc.
US_20260357219_A1

Absstract of: US20260357219A1

Apparatuses, systems, and methods are provided for culturing a buoyant target tissue using a sandwich construct. Embodiments include preparing a buoyant target tissue in a sandwich construct for shipment, and preparing a sandwich construct comprising live tumor tissue for evaluation of candidate therapies for treating the tumor. The buoyant target tissue may include various cell types including cancer cells and tumors.

DIAGNOSTIC USE OF HIGHLY TOXIC AMYLOID OLIGOMER

Publication No.:  US20260358351A1 12/11/2026
Applicant: 
SHEN ZHEN WISDOM BIOPHARM CO LTD [CN]
Shen Zhen Wisdom Biopharm Co., Ltd.
WO_2024032823_PA

Absstract of: US20260358351A1

A use of a new highly toxic amyloid oligomer Aβo*3F as a target for diagnosing Alzheimer's disease (AD) in the early stage and the middle-late stage and mild cognitive impairment (MCI) caused by AD. The Aβo*3F specifically binds to a antibody 3F and is present in cerebrospinal fluid (CSF), blood and/or brain tissue of AD patients and patients with MCI caused by AD, and the levels show highly significant differences in CSF, blood and/or brain tissue of AD patients, MCI patients and healthy elderly persons. In addition, the Aβo*3F is an ultra-highly toxic oligomer, is the most important toxic component in an Aβ oligomer mixture, has a strong pathogenic effect, and plays a key role in the occurrence and development of AD.

IDENTIFYING RISK OF AND TREATING STROKE-INDUCED COGNITIVE IMPAIRMENT FOLLOWING THROMBECTOMY

Publication No.:  US20260358355A1 12/11/2026
Applicant: 
UNIV OF KENTUCKY RESEARCH FOUNDATION [US]
University of Kentucky Research Foundation
US_20240036062_PA

Absstract of: US20260358355A1

Tools for identifying risk of and for treating vascular contributions to cognitive impairment and dementia (VCID) and stroke-induced cognitive impairment in a subject are provided and include a method and a device that involve detecting target proteins in systemic blood sample from the subject.

DIAGNOSTIC AGENT AND METHOD FOR ALZHEIMER'S DISEASE

Publication No.:  US20260358352A1 12/11/2026
Applicant: 
TEMASEK LIFE SCIENCES LABORATORY LTD [SG]
Temasek Life Sciences Laboratory Limited
WO_2024049357_PA

Absstract of: US20260358352A1

The invention relates to identification of an intron-retaining Tau splicing isoform as a novel Alzheimer's disease biomarker. Provided herein are polypeptides to generate binding molecules, such as antibodies specific for the Tau11i isoform, oligonucleotides and antibodies for use in methods for detecting the Tau11i isoform in a sample and methods for use in diagnosis for Alzheimer's disease.

Methods, Systems, and a Kit for Diagnosis, Detection, Monitoring and Treatment of Traumatic Brain Injury

Publication No.:  US20260358354A1 12/11/2026
Applicant: 
RAPIDDX INC [US]
RapidDx, Inc.
US_20260358354_A1

Absstract of: US20260358354A1

Methods and systems for diagnosis, detection, monitoring, and treatment of traumatic brain injury are described. The methods and systems include detection of salivary biomarkers associated with brain injury in a human subject, one application of which is to determine whether the subject has sustained a concussion or a more severe traumatic brain injury (TBI). Detection of the salivary biomarkers can also provide a basis to determine that a subject can safely return to play in an athletic event and can provide a basis to evaluate the efficacy of particular treatments. The methods and systems may be implemented, for example, by means of a kit.

BIOPANNING METHODS FOR IDENTIFYING PEPTIDES TARGETING GLIAL PHENOTYPES IN RAMIFIED, PRIMED, AND ACTIVATED BRAIN MICROGLIA AND ASTROCYTES

Publication No.:  US20260357477A1 12/11/2026
Applicant: 
NORTHWESTERN UNIV [US]
UNIV OF ALBERTA [CA]
Northwestern University
University of Alberta
US_20260357477_A1

Absstract of: US20260357477A1

0000 Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for identifying peptides that bind to glial cell subtypes including surveying glial cells, active glial cells, and/or primed glial cells.

THERAPEUTICALLY ACTIVE CELLS AND EXOSOMES

Publication No.:  US20260355253A1 12/11/2026
Applicant: 
CEDARS SINAI MEDICAL CENTER [US]
CAPRICOR INC [US]
Cedars-Sinai Medical Center
Capricor, Inc.
US_20260355253_A1

Absstract of: US20260355253A1

Several embodiments relate to methods of generating cells with therapeutic potency. Several embodiments relate to generating cells as a source of exosomes with therapeutic potency. The cells and exosomes with therapeutic potency are useful for repairing and/or regenerating damaged or diseased tissue, for example.

PROTEIN MARKER FOR ASSESSING AND TREATING NEURODEGENERATIVE DISEASES

Publication No.:  US20260358353A1 12/11/2026
Applicant: 
THE HONG KONG UNIV OF SCIENCE AND TECHNOLOGY [CN]
HONG KONG CENTER FOR NEURODEGENERATIVE DISEASES LTD [CN]
The Hong Kong University of Science and Technology
HONG KONG CENTER FOR NEURODEGENERATIVE DISEASES LIMITED
WO_2024074133_PA

Absstract of: US20260358353A1

Provided is a protein marker Nell-1, which is present in a person's blood sample in an amount that is correlated with neurodegenerative disorders such as Alzheimer's Disease (AD), Mild Cognitive Impairment (MCI), and Parkinson's Disease (PD). Corresponding diagnostic and treatment methods for these neurodegenerative disorders as well as kits for diagnosing or treating the neurodegenerative disorders are also provided.

Verfahren für die Diagnose einer neurodegenerativen Krankheit

Publication No.:  DE102025117473A1 12/11/2026
Applicant: 
SMATHERIA GGMBH [DE]
SMATHERIA gGmbH

Absstract of: DE102025117473A1

Die Erfindung betrifft ein Verfahren für die Diagnose einer neurodegenerativen Krankheit eines Individuums, bei dem in-vitro in einer biologischen Probe des Individuums eine für die Diagnose der neurodegenerativen Krankheit charakteristische Expression eines Proteins mittels einer Analyse eines für die Expression des Proteins spezifischen Biomarkers bestimmt wird.Die Erfindung zeichnet sich dadurch aus, dass das Protein ausgewählt ist aus HMG-CoA Synthase, SERPINA3, Pyruvat-Carboxylase, SCP-2, Myosin light polypeptide 6 und/oder Heat shock protein 60.Die Erfindung betrifft zudem zwei pharmazeutische Erzeugnisse sowie ein Kit und eine Verwendung.

PRIMATE MODEL OF CARDIAC ARRHYTHMIA REVEALS SLC41A2 AND A MAGNESIUM CLOCK IN PACEMAKER REGULATION

Publication No.:  WO2026236202A1 12/11/2026
Applicant: 
UNIV LELAND STANFORD JUNIOR [US]
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
WO_2026236202_A1

Absstract of: WO2026236202A1

Primate animal models of cardiac arrhythmias and methods of using such primate animal models for research and development and screening of therapeutics for treating cardiac arrhythmias are provided. In particular, lemurs were identified for use as animal models having different naturally occurring arrhythmias resembling human electrocardiographic (ECG) pathologies. In addition, genetically modified non-human primates and induced pluripotent stem cell-derived sinoatrial nodal pacemaker cells (iSANCs) comprising a loss-of-function mutation in an SLC41A2 gene linked to atrial arrhythmia and sinus node dysfunction and their use in screening therapeutics for treating atrial arrhythmia and sinus node dysfunction are also provided.

IN VITRO AND IN VIVO RECORDING OF CELL BASED DYNAMICS USING INTRACELLUAR PROTEIN TAPES

Publication No.:  WO2026236510A1 12/11/2026
Applicant: 
UNIV MICHIGAN REGENTS [US]
THE REGENTS OF THE UNIVERSITY OF MICHIGAN
WO_2026236510_A1

Absstract of: WO2026236510A1

Provided are compositions, systems, methods, and kits for genetically encoded, single-cell, spatiotemporally resolved, multiplexed recording of cellular activity in mammalian cells, including in living mammalian brain tissue. The disclosure provides self-assembling intracellular protein filaments, designated CytoTape and CytoTape-vivo, and corresponding nucleic acid constructs and recombinant viral vectors, that record one or more cellular activities and one or more user-defined temporal references as spatial distributions of detectable tags along the filament. The disclosure further provides systems and methods for brain-wide, single-cell, spatiotemporally resolved recording of cellular activity in non-human mammalian subjects, designated GLOBE recording, including recording of immediate-early-gene transcriptional activity at single-cell resolution across multiple anatomically distinct brain regions over multi-day recording windows. The disclosure further provides applications for characterizing gene regulatory networks, transcriptional dynamics, and brain-wide cellular activity in research, drug discovery, and disease-modeling contexts.

METHOD FOR QUANTIFYING PLASMALOGENS AND KIT FOR QUANTIFYING PLASMALOGENS

Publication No.:  EP4838226A1 11/11/2026
Applicant: 
INST OF RHEOLOGICAL FUNCTION OF FOOD CO LTD [JP]
UNIV KYUSHU NAT UNIV CORP [JP]
Institute of Rheological Function of Food Co., Ltd.
Kyushu University, National University Corporation
EP_4838226_PA

Absstract of: EP4838226A1

0001 A method of quantifying plasmalogen includes: a measurement sample preparation step of mixing a specimen containing protein and plasmalogen with Schiff reagent, to obtain a measurement sample; a control sample preparation step of mixing the specimen with a solvent of the Schiff reagent, to obtain a control sample; a measurement step of measuring a degree of a first optical property of the measurement sample after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen, and a degree of an optical property of the control sample; and a determination step of determining a plasmalogen concentration in the specimen by comparing a corrected degree obtained by correcting the degree of the first optical property with the degree of the optical property of the control sample, with a degree of a second optical property of a standard sample containing Schiff reagent and plasmalogen having a known concentration, the degree of the second optical property being obtained after reaction of the Schiff reagent with an aldehyde generated from a vinyl ether bond of the plasmalogen.

SURFACE FUNCTIONALIZED OPTICAL ELEMENT AND METHODS OF USE THEREOF

Publication No.:  EP4837918A1 11/11/2026
Applicant: 
BETASENSE GMBH [DE]
betaSENSE GmbH
EP_4837918_A1

Absstract of: EP4837918A1

The present invention relates to a surface-functionalized optical element comprising an IR-transparent optical element, wherein at least a part of the surface of the IR-transparent optical element is surface-functionalized, wherein said surface functionalization comprises a surface attachment moiety covalently attached to the surface of the IR-transparent optical element, and wherein at least part of the surface attachment moieties is covalently attached to a spacer moiety comprising a poly(alkylene oxide), wherein at least part of the spacer moieties is covalently attached to a charge optimization moiety, wherein said charge optimization moiety comprises a functional group that is charged under conditions of use of the optical element and optionally a poly(alkylene oxide), wherein at least part of the charge optimization moiety is covalently attached to a linker moiety comprising a poly(alkylene oxide), wherein at least part of the linker moieties is covalently attached to a molecular probe. The invention further relates to a single chain variable fragment (scFv) that can be used as a molecular probe for the capture of alpha-synuclein as well as sensor elements and sensors comprising said surface-functionalized optical element and/or scFv, and methods and uses thereof.

タウ認識抗体

Publication No.:  JP2026179489A 11/11/2026
Applicant: 
プロセナバイオサイエンシーズリミテッド
JP_2026179489_A

Absstract of: MX2021010517A

The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

白色光干渉法または原子間力顕微鏡法を使用してタンパク質症と関連付けられる分析物について生物学的流体試料をスクリーニングするための方法

Publication No.:  JP2026537624A 11/11/2026
Applicant: 
エフ.ホフマン-ラロシュアーゲー
JP_2026537624_A

Absstract of: WO2025073987A1

Disclosed herein is a device and method for measuring spatial mass distribution profiles to weigh the accumulated-aggregated mass of an analyte in a crowded bioorganic material background by employing a high frequency recognition pattern. The recognition pattern allows for the Fourier filtering of mass sensitive image data for background and noise subtraction. The device and method enables the screening of a biological fluid sample for an analyte associated with proteinopathy.

細胞外小胞組成物及びその使用

Publication No.:  JP2026537932A 11/11/2026
Applicant: 
イノヴィック・リミテッド
JP_2026537932_A

Absstract of: WO2025081242A1

The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.

双極性障害の治療標的の同定

Nº publicación: JP2026537430A 09/11/2026

Applicant:

ザ・ジョンズ・ホプキンス・ユニバーシティ

JP_2026537430_A

Absstract of: WO2025090981A1

The present disclosure provides a method of evaluating a mechanism of bipolar disorder, in particular mood switch, in human-derived neurons which may include providing a mechanism of an attenuated protein interaction of CaV1.2 and BK that can cause the calcium signaling deficit, the main cellular phenotype. The present disclosure further provides a method of evaluating a composition for efficacy in treating bipolar disorder, including providing a genetically modified mouse exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified mouse animal to a mild stressor; and determining whether the genetically modified mouse animal experiences a behavioral switch. The present disclosure also provides a method of treating bipolar disorder in a subject in need thereof, including administering to the subject a therapeutically effective amount of a BK channel agonist.

traducir